Question 73

Therapeutic duplication is a concern for a patient prescribed both Ventolin HFA and Xopenex HFA.

Both Ventolin HFA and Xopenex HFA are bronchodilators used in the treatment of asthma and other respiratory conditions. Prescribing them together can lead to therapeutic duplication, which may increase the risk of side effects without providing additional therapeutic benefit.

A) Spiriva Respimat and Dulera

Spiriva Respimat is a long-acting muscarinic antagonist (LAMA) and Dulera is a combination inhaler containing a corticosteroid and a long-acting beta-agonist (LABA). These medications serve different mechanisms and therapeutic purposes; therefore, using them together does not constitute therapeutic duplication.

B) Flovent HFA and Incruse Ellipta

Flovent HFA is an inhaled corticosteroid (ICS) while Incruse Ellipta is a LAMA. Both medications are used to manage respiratory conditions, but they target different pathways and do not overlap in their therapeutic effects, thus not representing therapeutic duplication.

C) Ventolin HFA and Xopenex HFA

Ventolin HFA and Xopenex HFA are both short-acting beta-agonists (SABAs) used for quick relief of asthma symptoms. Prescribing both can lead to therapeutic duplication, as they have similar actions and can increase the risk of side effects such as increased heart rate and nervousness without improving patient outcomes.

D) Serevent Diskus and Atrovent HFA

Serevent Diskus is a LABA and Atrovent HFA is an anticholinergic medication. These two medications work through different mechanisms and can be used together in a treatment plan without causing therapeutic duplication, as they do not overlap in their pharmacologic effects.

Conclusion

Ventolin HFA and Xopenex HFA exemplify therapeutic duplication as they are both SABAs with the same intended use and effects. The other options involve medications that serve distinct roles in managing respiratory conditions, making them appropriate to use in combination without the risks associated with therapeutic duplication. Thus, the concern for therapeutic duplication is specifically applicable to the combination of Ventolin HFA and Xopenex HFA.